BiotechTube
AffyImmune Therapeutics

AffyImmune Therapeutics

Natick, United States· Est.
affyimmune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $47M

Overview

AffyImmune Therapeutics is pioneering a novel approach to CAR T therapy aimed at overcoming the key challenges in treating solid tumors, such as on-target/off-tumor toxicity and lack of persistence. Its differentiated platform centers on affinity tuning against the ICAM-1 target and enabling noninvasive patient monitoring. The company has achieved significant regulatory milestones, including FDA RMAT designation for its lead program in anaplastic thyroid cancer, positioning it in the vanguard of solid tumor cell therapy development.

Oncology

Technology Platform

Affinity-tuned CAR T cell platform targeting ICAM-1 with integrated noninvasive monitoring capability.

Funding History

2
Total raised:$47M
Series B$26M
Series A$21M

Opportunities

The primary opportunity is addressing the catastrophic unmet need in anaplastic thyroid cancer, where a successful therapy can achieve high pricing and rapid uptake.
Success there provides a catalyst to expand into the vast non-small cell lung cancer market, representing a multi-billion dollar potential.
The proprietary noninvasive monitoring technology could also become a differentiated standard in cell therapy patient management.

Risk Factors

Key risks include clinical failure in ongoing trials, the inherent difficulty of making CAR T work in solid tumors due to the immunosuppressive microenvironment, and the complex, costly autologous manufacturing process.
The company is pre-revenue and will require significant additional financing, posing dilution and funding risks.

Competitive Landscape

AffyImmune competes in the crowded solid tumor cell therapy space, facing companies developing CAR T cells against other targets, Tumor-Infiltrating Lymphocytes (TILs), and other modalities. Its specific focus on ICAM-1 and thyroid cancer provides initial niche differentiation, but competition in NSCLC (its second indication) is intense from both cell therapies and targeted/biologic agents.

More companies in Cell & Gene Therapy →More companies in United States →